The latest price target for Pacific Biosciences (NASDAQ:PACB) was reported by Barclays on December 15, 2025. The analyst firm set a price target for $2.00 expecting PACB to fall to within 12 months (a possible -13.79% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacific Biosciences (NASDAQ:PACB) was provided by Barclays, and Pacific Biosciences maintained their equal-weight rating.

The last upgrade for Pacific Biosciences of California Inc happened on November 17, 2023 when UBS raised their price target to $10. UBS previously had a neutral for Pacific Biosciences of California Inc.

The last downgrade for Pacific Biosciences of California Inc happened on November 11, 2024 when UBS changed their price target from N/A to $2 for Pacific Biosciences of California Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on December 15, 2025 so you should expect the next rating to be made available sometime around December 15, 2026.

While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $1.50 to $2.00. The current price Pacific Biosciences (PACB) is trading at is $2.32, which is out of the analyst’s predicted range.